| Resource | CuraeLase, 12/11 | dbartel |
| Resource | Galloway Technologies, 8/11 | dbartel |
| Resource | Beckman Coultier, 11/11 | dbartel |
| Poll | According to the FDA's summary for 2010, what is the most frequently cited 483 topic for pharmaceutical manufacturers? | jmorris |
| Resource | EMA Reflection Paper on Risk Based Quality Management in Clinical Trials (2011 draft) | dbartel |
| Resource | FDA 483 Summary for Fiscal Year 2010 FREE | dbartel |
| Resource | ThyssenKrupp Access, 8/11 | dbartel |
| Resource | Bionet, 7/11 | dbartel |
| Resource | Noven Pharmaceuticals, 8/11 | dbartel |
| Resource | Luitpold Pharmaceuticals, 8/11 | dbartel |
| Poll | Per Japan’s GMP Guidelines for Computer Systems, the Design Qualification (DQ) validation step verifies: | jmorris |
| Resource | Japan Q&A on GMP Guideline on Managment of Computerized Systems | dbartel |
| Resource | Japan GMP Guideline on Managment of Computerized Systems | dbartel |
| Resource | Beckman Coulter, 8/11 | dbartel |
| Resource | Spinetronics, 7/11 | dbartel |
| Resource | Gulf Medical Fiberoptics, 7/11 | dbartel |
| Resource | Signal Medical, 6/11 | dbartel |
| Poll | Per the draft EU Guideline on distribution practices, what is the minimum time that back-up data be retained? | jmorris |
| Resource | EC Guidelines on Good Distribution Practice of Medicinal Products for Human Use 1992 | dbartel |
| Resource | UROMATRIX Medical Systems, 4/11 | dbartel |
| Resource | Philips Medical Systems, 6/11 | dbartel |
| Resource | Erchonia, 1/11 | dbartel |
| Resource | Compass International Innovations, 5/11 | dbartel |
| Resource | Biotech International, 10/10 | dbartel |
| Resource | Aubrey, 5/11 | dbartel |
